MOR News and Press, MorphoSys AG From 05/04/22

– Monjuvi ® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth – NCCN ® updated the designation of Monjuvi to preferred regimen in its Clinical Practice Guidelines in Oncolo...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / April 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST (9:00 pm GMT; 4:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on May 5, 2022 at 2:0...

FDA approved Pacritinib on Feb 28th, and the stock has appreciated more than 150%. However, the risk-reward has deteriorated significantly since our last article. The company does not have any more short-term catalysts, and considering that Pacritinib is an encumbered asset (deal with...

Morgan Stanley has upgraded Royalty Pharma (NASDAQ:RPRX +1.0%) to Overweight from Equal-weight, highlighting its valuation discrepancy relative to the sector. The analyst Terence Flynn notes that the buyer of biopharmaceutical royalties generated $2.6 billion of royalty revenue in 2021 thanks...

MorphoSys (NASDAQ:MOR) stock rose 11.6% after Berenberg began coverage of the company with Buy rating and a PT of €65. Berenberg analyst Xian Deng said shares have been under pressure since last year owing to increased competition in diffuse large B cell lymphoma treatments and now ass...

MorphoSys (NASDAQ:MOR) and partner Incyte (INCY) said the Swissmedic had granted temporary approval for their combination therapy, Minjuvi (tafasitamab) to treat relapsed or refractory diffuse large B-cell lymphoma. Minjuvi is given to DLBCL patinets in combination with Celgene...

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi (R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland ...

The ADRs of MorphoSys (MOR -9.7%) have recorded the biggest intraday loss since June Tuesday after both Deutsche Bank and Citi slashed their price targets on the German commercial-stage biopharmaceutical company. Arguing that the launch of the company’s lymphoma therapy, Monjuvi, ...

MorphoSys AG (MOR) Q4 2021 Results Conference Call March 17, 2022 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - Chief Executive Officer Sung Lee - Chief Financial Officer Malte Peters - Chief Research & Development Officer Joe Horvat - U.S. General Manager Confe...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q4 2021 Earnings Call Mar 17, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q4 2021 Earnings Call Transcript